ICML 2023 - 17th International Conference on Malignant Lymphoma
Jun 13 - Jun 17, 2023 | LuganoSwitzerland
LARVOL is not affiliated with 17th International Conference on Malignant Lymphoma and all trademarks, logos, and brand names are property of their respective owners
Showing 285 abstracts linked to Trials
BRECADD IS NON-INFERIOR TO EBEACOPP IN PATIENTS WITH ADVANCED STAGE CLASSICAL HODGKIN LYMPHOMA: EFFICACY RESULTS OF THE GHSG PHASE III HD21 TRIAL
PEMBROLIZUMAB AS FIRST THERAPY FOR HODGKIN LYMPHOMA IS DELIVERABLE IN OLDER OR ABVD-INELIGIBLE PATIENTS, ALLOWS SUBSEQUENT THERAPY, AND GIVES ADEQUATE SURVIVAL.
BASELINE PET RADIOMICS OUTPERFORMS CLINICAL RISK SCORES IN PREDICTING PRIMARY MEDIASTINAL B-CELL LYMPHOMA OUTCOME: INSIGHTS FROM THE IELSG37 STUDY
NIVOLUMAB(N)-AVD IMPROVES PROGRESSION-FREE SURVIVAL COMPARED TO BRENTUXIMAB VEDOTIN(BV)-AVD IN ADVANCED STAGE (AS) CLASSIC HODGKIN LYMPHOMA (HL): RESULTS OF SWOG S1826
FRONTLINE INTENSIFIED ABVD DEMONSTRATES SUPERIOR EFFICACY THAN PET-ADAPTED ABVD IN ADVANCED HODGKIN LYMPHOMA: THE FIL-ROUGE PHASE 3 TRIAL BY THE FONDAZIONE ITALIANA LINFOMI
LISOCABTAGENE MARALEUCEL (LISO-CEL) IN R/R CHRONIC LYMPHOCYTIC LEUKEMIA (CLL)/SMALL LYMPHOCYTIC LYMPHOMA (SLL): PRIMARY ANALYSIS OF TRANSCEND CLL 004
IBRUTINIB VERSUS PLACEBO IN PATIENTS WITH ASYMPTOMATIC, TREATMENT-NAïVE EARLY STAGE CHRONIC LYMPHOCYTIC LEUKEMIA (CLL): FINAL RESULTS OF THE CLL12 TRIAL
PHASE 2 TRIAL OF NIVOLUMAB PLUS ADRIAMYCIN, VINBLASTINE, DACARBAZINE (N-AVD) AS FRONTLINE THERAPY IN OLDER ADULTS WITH HODGKIN LYMPHOMA
LISOCABTAGENE MARALEUCEL (LISO-CEL) IN R/R MCL: PRIMARY ANALYSIS RESULTS FROM THE MCL COHORT OF THE SINGLE-ARM, MULTICENTER, SEAMLESS DESIGN TRANSCEND NHL 001 STUDY
PRIMARY OVERALL SURVIVAL ANALYSIS OF THE PHASE 3 RANDOMIZED ZUMA-7 STUDY OF AXICABTAGENE CILOLEUCEL VERSUS STANDARD OF CARE IN RELAPSED/REFRACTORY LARGE B-CELL LYMPHOMA
PHASE 3 TRIAL OF SUBCUTANEOUS EPCORITAMAB + R-CHOP VERSUS R-CHOP IN PATIENTS (PTS) WITH NEWLY DIAGNOSED DIFFUSE LARGE B-CELL LYMPHOMA (DLBCL): EPCORE DLBCL-2
ODRONEXTAMAB IN PATIENTS WITH RELAPSED/REFRACTORY DIFFUSE LARGE B-CELL LYMPHOMA (DLBCL): RESULTS FROM A PRESPECIFIED ANALYSIS OF THE PIVOTAL PHASE II STUDY ELM-2
R-CODOX-M/R-IVAC VERSUS DA-EPOCH-R IN PATIENTS WITH NEWLY DIAGNOSED HIGH-RISK BURKITT LYMPHOMA: FINAL RESULTS OF A MULTI-CENTER RANDOMIZED HOVON/SAKK TRIAL
BIOMARKER-DRIVEN TREATMENT STRATEGY IN HIGH-RISK LARGE B-CELL LYMPHOMA (NLG-LBC-06 PHASE II TRIAL): IMPACT OF CTDNA AND TP53 ABERRATIONS ON CLINICAL OUTCOME
CONSOLIDATIVE HCT-ASCT IS SUPERIOR TO NON-MYELOABLATIVE CHEMO-IMMUNOTHERAPY IN NEWLY-DIAGNOSED PCNSL - UPDATED RESULTS OF THE RANDOMIZED PHASE III MATRIX/IELSG43 TRIAL